Clinical Advantages of Neoadjuvant Docetaxel (T) and Carboplatin (C) ± Trastuzumab (H) in Locally Advanced Breast Cancer (LABC)

被引：0
|
作者：
Chang, H. R.
Glaspy, J.
Gornbein, J.
Kass, F. C.
Allison, M. A.
Chung, D. U.
机构：
[1] Univ Calif Los Angeles, Revlon UCLA Breast Ctr, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[3] Canc Ctr Santa Barbara, Santa Barbara, CA USA
[4] Comprehens Canc Ctr Nevada, Henderson, NV USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：571S / 571S
页数：1
相关论文
共 50 条
  • [1] Survival in patients with locally advanced breast cancer after neoadjuvant docetaxel (T), carboplatin (C), and trastuzumab (H)
    Chang, H. R.
    Prati, R.
    Gornbein, J. A.
    Chung, D.
    Glaspy, J. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Docetaxel and epirubicin as neoadjuvant chemotherapy (CT) in locally advanced breast cancer (LABC).
    Alkhatib, F
    Alawadi, S
    Grohn, P
    Motawy, M
    Fayaz, S
    Patel, J
    Attia, N
    Trad, D
    Delvadia, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 21 - 22
  • [3] Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): final analysis.
    Wildiers, H.
    Neven, P.
    Christiaens, M-R
    Fesneaux, G.
    Amant, F.
    Weltens, C.
    Smeets, A.
    van Limbergen, E.
    Debrock, G.
    Renard, V
    Paridaens, R.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 335S - 335S
  • [4] Preliminary results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC).
    Franco, SX
    Perez, A
    Frankel, C
    Tan-Chiu, E
    Schwartzberg, L
    Schwartz, M
    Krill, E
    Jakub, J
    Abramson, N
    Vogel, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 96S - 96S
  • [5] Neoadjuvant docetaxel (T), carboplatin (C), with or without trastuzumab (H) for T3 and T4 breast cancer.
    Chang, HR
    Slamon, D
    Chap, L
    Apple, S
    Glaspy, J
    Lee, P
    Malin, J
    Pegram, M
    Chung, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 89S - 89S
  • [6] Locally advanced breast cancer (LABC): Neoadjuvant chemotherapy with sequential doxorubicine (DOX) and docetaxel (DOC).
    Wynendaele, W
    Paridaens, R
    Wildiers, J
    Christiaens, MR
    Van den Bogaert, W
    van Oosterom, AT
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S208 - S208
  • [7] Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide plus /- Trastuzumab Followed by Docetaxel in Locally Advanced Breast Cancer (LABC)
    Tuxen, M. K.
    Cold, S.
    Tange, U. B.
    Soendergaard, S. B.
    Nielsen, D. L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S173 - S173
  • [8] Phase II study of neoadjuvant docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer (LABC)
    Perez-Manga, G.
    Mendez, M.
    Palomero, M. I.
    Quiben, R.
    Belon, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC):: preliminary safety and efficacy data from a multicentre phase II study
    不详
    [J]. EJC SUPPLEMENTS, 2006, 4 (02): : 157 - 158
  • [10] Multicentre phase II study of capecitabine (X), docetaxel (T) trastuzumab (H) as neoadjuvant treatment for patients (PTS) with locally advanced breast cancer (LABC): Preliminary safety and efficacy results
    Lybaert, Willem
    Wildiers, Hans
    Neven, Patrick
    Clement, Paul
    Amant, Frederic
    Christiaens, Marie-Rose
    Van Limbergen, Eric
    Weltens, Caroline
    Drijkoningen, Ria
    Paridaens, Robert
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
12345